Clinical Trials

These are all the clinical trials available. Choose a specialty if you want to narrow down the list.

Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers
This study consists of a physical screening session (scheduled between 8:00 am and 2:30 pm Monday through Friday) and seven study visits over a 13-week period. You may also be asked to come in for a follow-up visit six months after your quit day. Your entire participation, including six-month follow-up, will last approximately seven months.
The physical screening visit will take approximately 2 to 2 ½ hours, and includes a physical exam and a drug screening test. If you test positive for illegal drugs, you will not be eligible to participate. (REF# 00042699)

A Multicentre, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GFT505 once daily on Steatohepatitis in Patients with Non-Alcoholic Steatohepatitis (NASH)
The Primary Objective is to evaluate the efficacy of GFT505 80mg and GFT505 120mg daily versus placebo in reversing histological steatohepatitis without worsening of fibrosis. (REF# Pro00039585)

Smoking Asthmatics Research Study
Asthma patients who also smoke are needed to take part in a research study at the Duke Clinical Research Unit. The study will examine whether questionnaires used to evaluate asthma symptoms in non-smokers can also be applied to people with asthma who smoke. Participation will require 2 clinic visits that are approximately 6 weeks apart. (REF# 41549)

A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody against Lysyl Oxidase Like 2 (LOXL2) in Subjects with Primary Sclerosing Cholangitis (PSC)
The primary objective of this study is to evaluate whether GS-6624 is effective at preventing the progression of liver fibrosis in subjects with PSC. (REF# Pro00041834)

SOLAS® Spinal Surgery Registry: Prospective Clinical and Radiographic Outcomes Data Collection in Degenerative, Deformity, and Trauma Patients
The SOLAS Spinal Surgery Registry is a prospective multi-center observational data collection initiative, to capture clinical and radiographic outcomes in candidates for spine surgery with degenerative, deformity, and traumatic pathologies. As an observational database, there are no initial driving hypotheses, but rather data will be mined to answer unforeseen questions, but which may include broad topics such as comparative effectiveness between and among various surgical treatment options, and/or outcomes in various subgroups of patients such as defined by demographics, comorbidities, indications and symptoms, treatment variables, and/or outcome variables.
(REF# 3361)

A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects with Advanced Liver Fibrosis but not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH).
The primary objective of this study is: to evaluate whether GS-6624 is effective at preventing the progression of liver fibrosis in subjects with NASH. (REF# Pro00041486)

National Neurosurgery Quality and Outcomes Database (N2QOD): A Prospective Registry for Quality Reporting
The purpose of this national outcomes database is to assess to what extent lumbar spinal surgery improves pain, disability, and quality of life. To date, no nationally collaborative reporting mechanisms utilizing validated outcome measures have assessed lumbar spinal surgery outcomes. (REF# 29554)

Using Mobile Phone Text Messaging and E-mailing to Decrease Anxiety, Pain, Follow-up Visits and Improve Reporting of Surgical Site Infection after Spine Surgery: A Double-Blind Randomized Trial
The objectives of this double-blind, randomized controlled study are to evaluate the efficacy of maintaining contact with low-back pain patients through text messaging and emailing, to decrease anxiety levels, pain, number of follow-up visits through text messaging and emailing, and to improve reporting of surgical site infection after spine surgery through text messaging and emailing. (REF# 34182)

Multimodality Neuromonitoring in XLIF (NV in XLIF®)
This is a prospective, non-randomized multi-center study to evaluate intraoperative neuromonitoring results in subjects who undergo extreme lateral interbody fusion (XLIF) surgery at any number of levels inclusive of L4-5. (REF# 34204)

XLIF® vs. MAS®TLIF for the Treatment of Symptomatic Lumbar Degenerative Spondylolisthesis With or Without Central Stenosis
The purpose of this study is to determine differences in the XLIF and TLIF procedures with respect to perioperative variables in adult patients with low-grade symptomatic spondylolisthesis. (REF# 22589)

Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 of 18